The deal gives Merck control of Verona’s Ohtuvayre, a newly approved treatment for chronic obstructive pulmonary disease ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

Merck (MSD outside US & Canada) announces $10B acquisition of Verona Pharma to enhance its respiratory portfolio with COPD ...

Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to discuss Merck's (MRK) pending $10 billion acquisition ...

Merck & Co. said Wednesday it will acquire London-based Verona Pharma in a $10 billion all-cash deal, bolstering its respiratory treatment portfolio as the company moves to reduce long-term dependence ...

MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.

Pharmaceutical giant Merck & Co. (MRK) is buying British lung therapy firm Verona Pharma (VRNA) for $10 billion U.S. In a written statement, Merck said the deal will strengthen its respiratory ...

Google's Unloved Stock Makes It a Big Tech Bargain The search giant and its parent Alphabet face challenges that have pressured shares, but none is existential. Prosecutors Question Doctors About ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

CNBC's Angelica Peebles reports on themes emerging in the pharma space. Republican backs push to repeal part of Trump bill ...

Keytruda, the world's top-selling drug with nearly $30 billion in revenue last year, is nearing key patent expirations from ...

Merck to acquire Verona Pharma for $10 billion, adding COPD drug Ohtuvayre to strengthen respiratory portfolio.